Altamira Therapeutics Ltd (NAS:CYTO)

$ 0.9553 -0.0291 (-2.96%) Market Cap: 2.55 Mil Enterprise Value: 1.94 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 34/100

Full Year 2023 Altamira Therapeutics Ltd Earnings Call Transcript
Apr 10, 2024

$2 (+7.53%)

Earnings
Altamira Therapeutics Ltd to Host Investor & Business Update Call Transcript
Dec 11, 2023
Half Year 2023 Altamira Therapeutics Ltd Earnings Call Transcript
Sep 12, 2023

$6.39 (-6.03%)

Earnings
Q4 2022 Altamira Therapeutics Ltd Earnings Call Transcript
May 16, 2023

$17.99 (-3.87%)

Earnings
Altamira Therapeutics Ltd Business Update Conference Call Transcript
Sep 14, 2022
Q4 2021 Altamira Therapeutics Ltd Earnings Call Transcript
Apr 12, 2022

$456 (-31.33%)

Earnings
Altamira Therapeutics Ltd To Discuss Business Update Bentrio TM Transcript
Sep 27, 2021
Auris Medical Holding Ltd Acquires RNA Therapeutics Company - M&A Call Transcript
Jun 03, 2021
Q4 2020 Auris Medical Holding Ltd Earnings Call Transcript
Apr 13, 2021

$1720

Earnings
Half Year 2020 Auris Medical Holding Ltd Earnings Call Transcript
Sep 17, 2020

$327.36 (-1.68%)

Earnings
Q4 2019 Auris Medical Holding Ltd Earnings Call Transcript
Apr 16, 2020

$326.74 (-6.11%)

Earnings
Q2 2019 Auris Medical Holding Ltd Earnings Call Transcript
Aug 15, 2019

$1076 (-0.74%)

Earnings

Altamira Therapeutics Ltd To Discuss Business Update Bentrio TM Transcript

Sep 27, 2021 / 12:00PM GMT

Release Date Price: $920 (-3.77%)

Transcript

Operator

Good morning, and welcome to Altamira Therapeutics Conference Call. On today's call, Thomas Meyer, Altamira's Chairman and Chief Executive Officer, will provide an update on the company's Bentrio program.

During today's call, we will make forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These include statements that address future operating, financial or business performance or the company's strategies or expectations. Forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements.

These risks and uncertainties include, but are not limited to, the timing and conduct of the company's clinical trials, the clinical utility of its product candidates, the timing or likelihood of regulatory filings and approvals, the company's intellectual property position and its financial position as well as those described in the Risk Factors section

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.